New trial tests chemotherapy regimen following pancreatic cancer surgery
UC’s Ahmad leads SWOG national clinical trial
A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
The University of Cincinnati’s Syed Ahmad, MD, is the national principal investigator for the phase 2 Southwest Oncology Group (SWOG) 2104 trial.
Ahmad said he began work on this project several years ago in collaboration with Heloisa Soares, MD, PhD, of the University of Utah, through their collaboration as members of the cooperative SWOG Cancer Research Network.
The trial focuses on patients with pancreatic neuroendocrine tumors. The current standard of care for these patients is surgery only, followed by observation, but a subset of patients are at high risk for their cancer to return, Ahmad said.
Dr. Ahmad is the principal investigator of the SWOG 2104 clinical trial. Photo/UC Health.
“In the past, we would just watch and wait as no studies had proven beneficial to prevent recurrence," said Ahmad, University of Cincinnati Cancer Center co-director and professor of surgery in UC’s College of Medicine. “However, there was a recent study in patients with advanced cancer showing the efficacy of chemotherapy drugs capecitabine and temozolomide. So we proposed and opened this combination of drugs in patients who have had surgery but are at high risk of recurrence.”
In the trial, patients who have had pancreatic neuroendocrine tumors surgically removed will be randomized to two study arms. Select patients will either receive the two chemotherapy drugs or a placebo.
“The primary endpoint is to see if we can prevent recurrence of the cancer,” Ahmad said. If the treatment regimen proves successful, it could lead to improved survival rates for these patients, he said.
The study has just opened at UC and aims to enroll 150 patients at sites throughout the country. Ahmad said being part of the SWOG Cancer Research Network helps advance research and patient care.
“It allows us to open studies at hundreds of sites to help with trial enrollment,” he said. “It allows us to open novel studies from other institutions so that our local patients have access to cutting edge therapy.”
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Featured photo at top of Dr. Ahmad. Photo/University of Cincinnati Cancer Center.
Related Stories
What would expanded access to GLP-1s mean for the obesity rate?
December 4, 2025
The World Health Organization recently issued its first guidance on GLP-1 medications for adults with obesity — recommending long-term, continuous use when clinically appropriate. Malti Vij, MD, University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine, appeared on Cincinnati Edition on 91.7 WVXU News to discuss GLP-1s and what expanded insurance coverage of the medications might mean for Americans.
Teaching empathy and courage
December 4, 2025
Two University of Cincinnati co-op students engage children in hands-on “Superhero Activation” activities at the Nancy & David Wolf Holocaust & Humanity Center, helping young visitors learn kindness, courage and how to be upstanders.
Feast of Carols features holiday hits, local choirs in concert Dec. 6-7
December 3, 2025
UC College-Conservatory of Music welcomes the holiday season with its annual Feast of Carols concerts on Dec. 6-7, 2025 in Corbett Auditorium. Tickets are on sale now through the CCM Box Office.